Other equities analysts also recently issued reports about the stock. HC Wainwright initiated coverage on shares of NeuBase Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer began coverage on shares of NeuBase Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $14.00 target price on the stock. Finally, BTIG Research began coverage on shares of NeuBase Therapeutics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price target on the stock.
Shares of NBSE stock opened at $6.01 on Wednesday. The stock’s 50-day moving average price is $4.96. NeuBase Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.95.
NeuBase Therapeutics Company Profile
NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.
Further Reading: What is meant by holder of record?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.